Sedation with Sevoflurane versus Propofol in COVID-19 Patients with Acute Respiratory Distress Syndrome: Results from a Randomized Clinical Trial

Background: Acute respiratory distress syndrome (ARDS) related to COVID-19 (coronavirus disease 2019) led to intensive care units (ICUs) collapse. Amalgams of sedative agents (including volatile anesthetics) were used due to the clinical shortage of intravenous drugs (mainly propofol and midazolam). Methods: A multicenter, randomized 1:1, controlled clinical trial was designed to compare sedation using propofol and sevoflurane in patients with ARDS associated with COVID-19 infection in terms of oxygenation and mortality. Results: Data from a total of 17 patients (10 in the propofol arm and 7 in the sevoflurane arm) showed a trend toward PaO2/FiO2 improvement and the sevoflurane arm’s superiority in decreasing the likelihood of death (no statistical significance was found). Conclusions: Intravenous agents are the most-used sedative agents in Spain, even though volatile anesthetics, such as sevoflurane and isoflurane, have shown beneficial effects in many clinical conditions. Growing evidence demonstrates the safety and potential benefits of using volatile anesthetics in critical situations.

[1]  J. Bazin,et al.  Use of volatile anesthetics for sedation in the ICU during the COVID-19 pandemic: A national survey in France (VOL’ICU 2 study) , 2022, PloS one.

[2]  J. Divatia,et al.  Safety and Feasibility of AnaConDa™ to Deliver Inhaled Isoflurane for Sedation in Patients Undergoing Elective Postoperative Mechanical Ventilation: A Prospective, Open-label, Interventional Trial (INSTINCT I Study) , 2022, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[3]  T. Shiga,et al.  Sevoflurane administration from extracorporeal membrane oxygenation via the AnaConDa device for a patient with COVID-19: A breakthrough solution for the shortage of intravenous anesthetics , 2022, Heart & Lung.

[4]  J. Constantin,et al.  Inhaled Sedation in Patients with COVID-19-Related Acute Respiratory Distress Syndrome: An International Retrospective Study , 2022, Journal of clinical medicine.

[5]  G. Landoni,et al.  Inhaled Sedation for Invasively Ventilated COVID-19 Patients: A Systematic Review , 2022, Journal of clinical medicine.

[6]  S. Heinrich,et al.  Sevoflurane in combination with esketamine is an effective sedation regimen in COVID-19 patients enabling assisted spontaneous breathing even during prone positioning , 2022, Anaesthesiology intensive therapy.

[7]  P. Póvoa,et al.  Practices in sedation, analgesia, mobilization, delirium, and sleep deprivation in adult intensive care units (SAMDS-ICU): an international survey before and during the COVID-19 pandemic , 2022, Annals of Intensive Care.

[8]  U. Guenther,et al.  Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. , 2021, The Lancet. Respiratory medicine.

[9]  R. Bals,et al.  Comparison of isoflurane and propofol sedation in critically ill COVID-19 patients—a retrospective chart review , 2021, Journal of Anesthesia.

[10]  M. Rech,et al.  Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study , 2021, The Annals of pharmacotherapy.

[11]  Kevin R. Donahue,et al.  Approach to Sedation and Analgesia in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation , 2021, The Annals of pharmacotherapy.

[12]  H. Ramakrishna,et al.  2021 Acute Respiratory Distress Syndrome Update, With Coronavirus Disease 2019 Focus , 2021, Journal of Cardiothoracic and Vascular Anesthesia.

[13]  Isam K. Bsisu,et al.  Sedating Mechanically Ventilated COVID-19 Patients with Volatile Anesthetics: Insights on the Last-Minute Potential Weapons , 2021, Scientia Pharmaceutica.

[14]  J. Payen,et al.  Analgesia and sedation in patients with ARDS , 2020, Intensive Care Medicine.

[15]  A. Flinspach,et al.  Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review , 2020, Critical care explorations.

[16]  V. Kaura,et al.  Sevoflurane may not be a complete sigh of relief in COVID-19 , 2020, British Journal of Anaesthesia.

[17]  S. Kane-Gill,et al.  Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages , 2020, Journal of intensive care medicine.

[18]  Jeongmin Kim,et al.  Inhalation sedation for postoperative patients in the intensive care unit: initial sevoflurane concentration and comparison of opioid use with propofol sedation , 2020, Acute and critical care.

[19]  M. Raux,et al.  Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals? , 2020, Anaesthesia Critical Care & Pain Medicine.

[20]  B. Cuthbertson,et al.  Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS , 2020, Intensive Care Medicine.

[21]  A. Shuman,et al.  Preparing for COVID-19–related Drug Shortages , 2020, Annals of the American Thoracic Society.

[22]  M. Struys,et al.  Sevoflurane, a sigh of relief in COVID-19? , 2020, British Journal of Anaesthesia.

[23]  J. Payen,et al.  Sedation for critically ill patients with COVID-19: Which specificities? One size does not fit all , 2020, Anaesthesia Critical Care & Pain Medicine.

[24]  B. Orser,et al.  Sedating ventilated COVID-19 patients with inhalational anesthetic drugs , 2020, EBioMedicine.

[25]  D. Needham,et al.  Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU , 2018, Critical care medicine.

[26]  A. Mebazaa,et al.  Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. , 2018, Anaesthesia, critical care & pain medicine.

[27]  H. Kim,et al.  Volatile sedation in the intensive care unit , 2017, Medicine.

[28]  D. Schwartz,et al.  Isoflurane promotes phagocytosis of apoptotic neutrophils through AMPK-mediated ADAM17/Mer signaling , 2017, PloS one.

[29]  S. Keshavjee,et al.  Sevoflurane Attenuates Ischemia-Reperfusion Injury in a Rat Lung Transplantation Model. , 2017, The Annals of thoracic surgery.

[30]  A. Jerath,et al.  Safety and Efficacy of Volatile Anesthetic Agents Compared With Standard Intravenous Midazolam/Propofol Sedation in Ventilated Critical Care Patients: A Meta-analysis and Systematic Review of Prospective Trials , 2017, Anesthesia and analgesia.

[31]  A. Wolf,et al.  Delir, Analgesie und Sedierung in der Intensivmedizin , 2017, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[32]  J. Bazin,et al.  Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study , 2016, American journal of respiratory and critical care medicine.

[33]  W. Uhl,et al.  Survival after long-term isoflurane sedation as opposed to intravenous sedation in critically ill surgical patients: Retrospective analysis , 2016, European journal of anaesthesiology.

[34]  V. Rao,et al.  Volatile-Based Short-Term Sedation in Cardiac Surgical Patients: A Prospective Randomized Controlled Trial , 2015, Critical care medicine.

[35]  C. Ferrando,et al.  Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: A randomised laboratory study , 2013, European journal of anaesthesiology.

[36]  Arthur S Slutsky,et al.  Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury , 2012, Intensive Care Medicine.

[37]  C. Booy,et al.  Sevoflurane reduces severity of acute lung injury possibly by impairing formation of alveolar oedema , 2012, Clinical and experimental immunology.

[38]  S. Jaber,et al.  Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam , 2011, Intensive Care Medicine.

[39]  M. Urner,et al.  Sevoflurane Ameliorates Gas Exchange and Attenuates Lung Damage in Experimental Lipopolysaccharide-induced Lung Injury , 2009, Anesthesiology.

[40]  D. Spahn,et al.  The volatile anaesthetic sevoflurane attenuates lipopolysaccharide‐induced injury in alveolar macrophages , 2009, Clinical and experimental immunology.

[41]  R. Badenes,et al.  The Predictive Performance of a Pharmacokinetic Model for Manually Adjusted Infusion of Liquid Sevofluorane for Use with the Anesthetic-Conserving Device (AnaConDa): A Clinical Study , 2008, Anesthesia and analgesia.

[42]  P. Sackey,et al.  Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam—A pilot study* , 2008, Critical care medicine.

[43]  D. Spahn,et al.  The Immunomodulatory Effect of Sevoflurane in Endotoxin-Injured Alveolar Epithelial Cells , 2007, Anesthesia and analgesia.

[44]  Gordon R Bernard,et al.  Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.

[45]  A. Meiser,et al.  Inhalational anaesthetics in the ICU: theory and practice of inhalational sedation in the ICU, economics, risk-benefit. , 2005, Best practice & research. Clinical anaesthesiology.

[46]  F. Granath,et al.  Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device , 2004, Critical care medicine.

[47]  M. Bellgardt,et al.  Desflurane compared with propofol for postoperative sedation in the intensive care unit. , 2003, British journal of anaesthesia.

[48]  S. Willatts,et al.  Isoflurane compared with midazolam for sedation in the intensive care unit. , 1989, BMJ.

[49]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[50]  P. Kellner,et al.  Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury , 2017, Anesthesia and analgesia.

[51]  J. Bazin,et al.  Simple assay of plasma sevoflurane and its metabolite hexafluoroisopropanol by headspace GC-MS. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[52]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.